Group 1 - The core point of the news is that Huang Qianyi, a shareholder holding over 5% of Huayu Pharmaceutical, has had 27.22 million shares frozen due to a private lending dispute with Jin Zuping, which represents 6.426% of the company's total share capital [1] - The court has not yet heard the case regarding the asset preservation application filed by Jin Zuping [1] - On March 31, Huayu Pharmaceutical announced that Huang Qianyi intended to reduce his holdings by up to 12.7 million shares, not exceeding 3% of the total shares, due to personal funding needs [3] Group 2 - Huayu Pharmaceutical, established in 2010 and located in Sichuan Neijiang, is a research-driven comprehensive pharmaceutical company focused on the R&D, production, and sales of anti-tumor drugs and injectables [3] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2021, with Ding Zhaowei as the actual controller [3] - For the period from January to March 2025, Huayu Pharmaceutical reported revenue of 239 million yuan, a year-on-year decrease of 1.46%, and a net loss attributable to shareholders of 25.63 million yuan, a year-on-year decrease of 155.19% [3] - As of the close on the 25th, Huayu Pharmaceutical's stock price was 16.51 yuan per share, down 3.05%, with a total market capitalization of 6.994 billion yuan [3]